Ulteriori informazioni
This book offers an in-depth analysis of enzyme-based approaches in healthcare management, focusing on their transformative potential in cancer treatment. This volume delves into the intricate roles of enzymes in cancer progression and targeted therapy.
The book addresses a wide range of subjects, such as the functions of important enzymes in the biology of cancer, developments in targeting telomerase, the cell cycle, angiogenesis, and metastasis, and the possibility of using topoisomerase and PARP inhibitors to take advantage of weaknesses in cancer cells. It provides an in-depth analysis of non-glycolytic and glycolytic enzymes, tumor-driven angiogenesis, epigenetic regulation, and advanced therapeutic approaches, including nanotechnology and bispecific antibodies. It addresses key questions such as how enzymes contribute to cancer metabolism and how novel therapeutic strategies can exploit these pathways for more accurate and less dangerous cancer medicines. The book covers expert analyses of key enzymes involved in cancer biology, including hexokinase, phosphofructokinase-1, and matrix metalloproteinases.
This book is an invaluable resource for researchers, clinicians, and professionals in the pharmaceutical and biotechnology industries. It offers a comprehensive overview of the molecular mechanisms underlying enzyme function in cancer and the development of innovative enzyme-targeted treatments. It is a must-read for those seeking to advance their understanding of enzyme-based healthcare management.
Sommario
Section I: Non-Glycolytic and Glycolytic Enzymes in Cancer Progression and Targeted Therapy.- Chapter 1. Hexokinase (HK).- Chapter 2. Glucose-6-Phosphate Isomerase (G6PI).- Chapter 3. Phosphofructokinase-1 (PFK-1).- Chapter 4. Aldolase: Functions in Glycolysis and Epithelial-Mesenchymal Transition (EMT).- Chapter 5. Glyceraldehyde-3-Phosphate Dehydrogenase (GA3PDH): Role in Membrane Transport and Plasminogen Binding.- Section II: Enzymes Involved in Tumor-Driven Angiogenesis.- Chapter 6. Receptor Tyrosine Kinase (RTK).- Chapter 7. Nitric Oxide Synthase (NOS).- Chapter 8. Matrix Metalloproteinase (MMP).- Chapter 9. Thymidine Phosphorylase.- Chapter 10. Cathepsin Proteases.- Section III: Epigenetics and Enzyme Inhibition.- Chapter 11. DNA Methyltransferases (DNMTs) DNMT1, DNMT2, DNMT3A, DNMT3B, DNMT3L.- Chapter 12. Restoring Tumor Suppression Activity: Mimicking Molecules (TargomiRs and MRX34), and Synthetic RNAs (MTL-CEBPA).- Chapter 13. Inhibiting Oncogene Expression through Molecules that Degrade mRNAs: MRG-106 and Dovitinib .- Chapter 14. Histone and Histone Family: Histone Modification, Histone Acetyltransferases, Histone Methyltransferases, Methyl-Histone Recognition Proteins, Histone Demethylases, and Histone Deacetylation Inhibitors (HDACi).- Section IV: Advanced Therapeutic Approaches.- Chapter 15. Bispecific Antibodies in Cancer Therapy.- Chapter 16. Nanotechnology in Targeting Enzymes in Cancer Therapy.
